AI Terminal
Johnson Matthey PLC
M&A Activity • Jul 1, 2024
4899_rns_2024-07-01_dd340ad2-a299-4f69-80df-8ed78f46cc48.html
M&A Activity
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5829U
Johnson Matthey PLC
01 July 2024
Johnson Matthey announces completion of Medical Device Components sale
1st July 2024
| Further to the announcement on 20th March 2024, Johnson Matthey Plc (JM) is pleased to announce that it has today completed the sale of its Medical Device Components business (MDC) in accordance with the terms of the sale agreement entered into between JM and Montagu Private Equity for cash consideration of US$700 million (£550 million) on a cash free debt free basis. |
| The board confirms its intention to return £250 million of the net proceeds from the sale of MDC by way of an on-market share buyback programme. This will commence later this week and further details will be announced in due course. |
| ENDS |
| Enquiries: | ||
| Investor Relations | ||
| Martin Dunwoodie Louise Curran |
Director of Investor Relations and Treasury Head of Investor Relations |
+44 20 7269 8241 +44 20 7269 8235 |
| Chris Wood | Senior Investor Relations Manager | +44 20 7269 8138 |
| Media | ||
| Sinead Keller Harry Cameron |
Group External Relations Director Teneo |
+44 20 7269 8218 +44 7799 152148 |
| Johnson Matthey Plc is listed on the London Stock Exchange (JMAT) |
| Registered in England & Wales number: 00033774 |
| Legal Entity Identifier number: 2138001AVBSD1HSC6Z10 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DISSSDSAFELSELW